03:54 PM EST - Lorus Therapeutics Inc. : announced the addition of MD Anderson Cancer Center as a second site in the ongoing Lorus Phase I clinical trial with its first-in-class anticancer drug LOR-253. Lorus Therapeutics Inc.
shares T.LOR are trading up $0.135 at $0.58.
